Paul Sargos, MD, Institut Bergonié, Bordeaux, France, discusses the challenges in managing localized muscle-invasive bladder cancer (MIBC) and emphasizes the need for improved patient selection. Dr Sargos explores the decision-making process between radical cystectomy, neoadjuvant chemotherapy, and radiochemotherapy, highlighting the importance of biomarkers. PD-L1 status is considered, with promising data for perioperative immunotherapy in surgery. Ongoing research investigates the combination of radiotherapy and immunotherapy. Dr Sargos additionally mentions the potential of a biomarker, Mir-11, to predict radiotherapy sensitivity. This interview took place at the Global Congress on Prostate and Bladder Cancer (PROSCA/BLADDR) 2023 in Malaga, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
